Hengrui Medicine
Hengrui is the Pfizer of China; it survived brutal pricing crackdowns by ruthlessly reinvesting its profits to transform from a legacy generic manufacturer into an innovative powerhouse.
Revenue
$3.9B
~$3.9 billion USD
Profitability
Highly Profitable
Division
Healthcare and Biotech
Public
Headquarters
Lianyungang
Sun Piaoyang
Operating Model
What They Do
Hengrui commercializes proprietary novel therapeutics in oncology, metabolic diseases, and immunology.
Who They Serve
The Chinese domestic healthcare market and global pharma giants via licensing.
Moat: Where They Win
The Innovation Pivot
When the government slashed generic prices, Hengrui survived because it had aggressively pivoted to new inventions.
Distribution
Employs a massive sales force with relationships with virtually every major Chinese oncologist.
Licensing
Western giants like Merck are paying hundreds of millions to license Hengruis new molecules.
Business Model
Model Type
Revenue Streams
Profitability
Status
Highly Profitable
Revenue
$3.9B
est.
Division
Healthcare and Biotech
Public
Margin Profile
Strongly profitable. Net profits surged in 2025 as innovative drugs reached over 50 percent of total revenue.
Catalyst: Why Now
Hengrui's 2025 earnings prove the transition from cheap generics to premium innovative drugs is complete, with profit growth surging nearly 50 percent.
Competitive Landscape
* Competitive threat index · China domestic market positioning
Western Analogs
Mental model only, not a 1:1 comparison
Founder
Sun Piaoyang
Founder & CEO
Sun took over a struggling factory at age 32 and spent its entire capital to buy an anti cancer patent, anticipating crackdowns on generics decades in advance.